TY - JOUR T1 - Microarray Analysis of MCF-7 Breast Cancer Cells Treated with 1,25-Dihydroxyvitamin D<sub>3</sub> or a 17-Methyl-D-ring Analog JF - Anticancer Research JO - Anticancer Res SP - 3585 LP - 3590 VL - 29 IS - 9 AU - ELS VANOIRBEEK AU - GUY EELEN AU - LIEVE VERLINDEN AU - KATHLEEN MARCHAL AU - KRISTOF ENGELEN AU - BART DE MOOR AU - INE BEULLENS AU - SUZANNE MARCELIS AU - PIERRE DE CLERCQ AU - ROGER BOUILLON AU - ANNEMIEKE VERSTUYF Y1 - 2009/09/01 UR - http://ar.iiarjournals.org/content/29/9/3585.abstract N2 - Background: 1α,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is the biological active form of vitamin D. Its antiproliferative capacities make it a potential drug to treat diseases such as cancer. The clinical use of 1,25-(OH)2D3 as an antiproliferative agent is hampered by its calcemic effects. Hence, structural analogs such as the seco-9,11-bisnor-17-methyl analog, WY1112, have been developed with superagonistic capacities. This study aims to distinct the molecular activities of 1,25-(OH)2D3 and WY1112 and identify possible differences in gene expression. Materials and Methods: Total RNA was extracted from MCF-7 breast cancer cells treated with 1,25-(OH)2D3 or WY1112 and was used for microarray analysis. Results: The experiments revealed that WY1112 induces the same genes as 1,25-(OH)2D3, but the induction level of the individual genes is higher. Microarray analysis did not reveal genes that were exclusively regulated by WY1112. Conclusion: The superagonistic vitamin D analog WY1112 induces the same set of genes as 1,25-(OH)2D3, but the level of induction of the individual genes is higher. ER -